Trial Profile
Efficacy of MAGE-A3 immunotherapeutic in patients with MAGE-A3 positive, stage IB/II, non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Zastumotide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.